Bridging iron and lung injury: the emerging role of ferroptosis in ARDS Authors: Yuanjun Zhang, Ji Luo, Zhiqiang Tang, Hui Gao Published: 2025 ABSTRACT AbstractAcute respiratory distress syndrome (ARDS) is a severe and diffuse inflammatory lung injury induced by various pulmonary or systemic insults. Its characteristics include disruption of the alveolar–capillary barrier, protein-rich exudates, and refractory hypoxemia. It has a high clinical mortality rate and lacks specific therapies targeting the core mechanisms. Ferroptosis is a regulated, non-apoptotic form of cell death that depends on iron ions and lipid peroxidation. Since its discovery, it has been shown to play a significant role in the pathogenesis of various diseases. Recent studies have demonstrated that ferroptosis plays a critical role in acute lung injury/ARDS. Moreover, it exhibits both commonalities and differences across ARDS of various etiologies. This review systematically summarizes the definition and key mechanisms of ferroptosis, as well as its functional characteristics in different types of ARDS. It also discusses the interaction mechanisms between ferroptosis and ARDS, ferroptosis-targeted interventions, and relevant clinical studies. In addition, it analyzes existing controversies in this field. It also presents prospects for potential breakthroughs in ferroptosis research related to ARDS. The aim is to provide a reference for the study of ARDS pathogenesis and the development of diagnostic and therapeutic strategies based on ferroptosis.Keywords: Ferroptosis, ARDS, Interventional strategies, Biomarkers Introduction ARDS is a life-threatening diffuse lung injury, clinically characterized by acute, bilateral diffuse inflammatory damage, accompanied by impaired alveolar ventilation, refractory hypoxemia, and decreased lung compliance. According to the Berlin definition, mild ARDS is defined by a PaO2/FiO2 ratio of 200 mmHg < PaO2/FiO2 ≤ 300 mmHg, moderate as 100 mmHg < PaO2/FiO2 ≤ 200 mmHg, and severe as PaO2/FiO2 ≤ 100 mmHg, with mild ARDS also referred to as acute lung injury (ALI) [1, 2]. ARDS can be triggered by various factors, including pneumonia, aspiration of gastric contents, inhalation injury, sepsis, severe trauma, and drowning [3, 4]. Despite different etiologies, the shared pathogenesis involves damage to the alveolar epithelium–capillary endothelium barrier and accumulation of protein-rich exudate in the alveolar interstitium, leading to alveolar collapse, impaired gas exchange, and respiratory failure [5]. The incidence of ARDS in Intensive Care Unit (ICU) patients is approximately 10%, with a mortality rate as high as 35–46%. Currently, there are no specific therapeutic drugs, and treatment mainly relies on supportive measures, such as mechanical ventilation and extracorporeal membrane oxygenation [5, 6]. Since the end of 2019, the COVID-19 pandemic has further exacerbated the clinical challenges of ARDS. Ferroptosis is a form of iron-dependent regulated cell death identified in 2012, induced by erastin and Ras-selective lethal 3(RSL3), and it is distinct from other forms of cell death, such as apoptosis and necrosis [7, 8]. The hallmark of ferroptosis is the iron-dependent accumulation of excessive lipid peroxidation products within cells, morphologically characterized by mitochondrial shrinkage, increased membrane density, and iron accumulation, without the typical morphological changes seen in apoptosis or necrosis. Ferroptosis is closely associated with intracellular iron metabolism, cysteine/glutathione metabolism, and polyunsaturated fatty acid (PUFA) metabolism [9]. Recent studies have shown that ferroptosis is involved in the pathogenesis of various diseases, including cancer, neurodegeneration, liver and kidney injury, ischemia–reperfusion injury, and a range of inflammatory diseases [9, 10]. Emerging research suggests that ferroptosis also plays a key role in acute lung injury/ARDS, with its regulatory mechanisms closely linked to inflammation and oxidative stress in ARDS [10]. For example, multiple experiments have shown that molecules inhibiting ferroptosis (such as Ferrostatin-1 and Liproxstatin-1) can alleviate lung tissue injury and inflammation in ARDS models [10, 11]. Therefore, elucidating the molecular mechanisms of ferroptosis, its role in different types of ARDS, the interaction between ferroptosis and ARDS, as well as relevant therapeutic interventions and clinical studies, will provide valuable insights for understanding the pathogenesis of ARDS and developing ferroptosis-based diagnostic and therapeutic strategies. Pathophysiological mechanisms of ARDS The pathophysiological mechanisms of ARDS are complex and involve multiple processes, such as inflammatory responses, oxidative stress, disruption of the alveolar–capillary barrier, and cell death. Inflammatory response plays a critical role in the onset and progression of ARDS, with various inflammatory cells such as neutrophils and macrophages being activated to release large quantities of inflammatory mediators, including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), thereby triggering systemic inflammatory response syndrome and leading to pulmonary inflammatory injury [12]. Oxidative stress is also a key pathological feature of ARDS, characterized by an imbalance between oxidative and antioxidant systems in the body, leading to excessive production of reactive oxygen species (ROS) that damage cells and tissues. Meanwhile, damage to the alveolar–capillary barrier causes intravascular fluids and proteins to leak into the alveolar space, resulting in pulmonary edema, impaired gas exchange, and hypoxemia [13]. In addition, cellular death mechanisms such as apoptosis and necrosis are also involved in the pathogenesis of ARDS. Apoptosis of epithelial cells compromises the integrity of the alveolar epithelium, thereby impairing alveolar fluid clearance and gas exchange; excessive infiltration and death of inflammatory cells further exacerbate the inflammatory response and tissue injury [14]. These pathophysiological processes interact with each other to form a vicious cycle that ultimately leads to the onset and progression of ARDS. Ferroptosis: definition and key mechanisms Ferroptosis is an iron-dependent, regulated cell death driven by lethal lipid peroxide accumulation. Its biochemical hallmark is that when intracellular iron drives lipid peroxidation to levels that overwhelm antioxidant defenses, membrane lipids undergo irreversible damage, ultimately resulting in cell death [11]. This concept was first proposed by Dixon et al. in 2012, when they observed a non-apoptotic, iron-dependent form of cell death in cancer cells treated with erastin, which they named ferroptosis [7]. Unlike apoptosis, pyroptosis, or necroptosis, ferroptosis is morphologically characterized by reduced mitochondrial volume, decreased cristae, increased membrane density; however, chromatin condensation is not present; membrane rupture may be observed at later stages. At the molecular level, its core mechanism involves iron-dependent dysregulation of membrane lipid peroxidation, rather than caspase activation or receptor-interacting serine/threonine–protein kinase 3/mixed lineage kinase domain-like protein-mediated pathways [11]. The main metabolic mechanisms of ferroptosis can be divided into three pillars: iron metabolism, lipid peroxidation, and the glutathione-dependent antioxidant system, along with a parallel ferroptosis suppressor protein 1(FSP1)–coenzyme Q10(CoQ10)–nicotinamide adenine dinucleotide phosphate (NADPH) ferroptosis defense pathway [15]. When intracellular iron homeostasis is disrupted, excess free Fe2⁺ promotes ROS generation via the Fenton reaction or iron-dependent enzymes (e.g., lipoxygenases), thereby driving lipid peroxidation of polyunsaturated fatty acids, which damages membrane structure and impairs function. Meanwhile, the glutamate–cystine antiporter system Xc– imports extracellular cystine for intracellular synthesis of glutathione (GSH), and Glutathione Peroxidase 4 (GPX4) uses GSH as a reducing substrate to eliminate lipid peroxides in membranes, this axis forms the core of the cell’s antioxidant defense. When system Xc– is inhibited or GPX4 is inactivated, lipid peroxides accumulate unchecked, triggering ferroptosis. Recent studies have shown that the FSP1–coenzyme Q10 (CoQ10)–NADPH pathway acts as a parallel compensatory mechanism to the GPX4/GSH axis, also reducing lipid radicals and suppressing ferroptosis. Therefore, the cellular sensitivity to ferroptosis is jointly determined by iron homeostasis, lipid peroxidation levels, and the glutathione/GPX4 antioxidant system [11, 16–18]. Schematic diagram of the main molecular mechanism of ferroptosis as shown in Fig. 1. Schematic diagram of the main molecular mechanism of ferroptosis. TfR mediates Fe3⁺ uptake, while Ferritin/NCOA4 regulates iron storage and release, the resulting excess Fe2⁺ catalyzes the Fenton reaction, leading to ROS accumulation and triggering ferroptosis; System Xc⁻ supplies cystine for GSH synthesis, and GPX4 uses GSH to eliminate lipid peroxides, thereby reducing ROS accumulation and inhibiting ferroptosis; FSP1 reduces coenzyme Q10 under the catalysis of NADPH, acting as an antioxidant to prevent ROS buildup and suppress ferroptosis. The figure is generated by Figdraw. TFR Transferrin receptor; NCOA4 nuclear receptor coactivator 4; System Xc- cystine/glutamate transporter; GSH glutathione; GPX4 glutathione peroxidase 4; PUFA polyunsaturated fatty acid; FSP1 ferroptosis suppressor protein 1; CoQ10 coenzyme Q10; NADPH nicotinamide adenine dinucleotide phosphate Characteristics of ferroptosis in different types of ARDS In recent years, ferroptosis, a novel form of iron-dependent, lipid peroxidation-mediated programmed cell death, has emerged as a key player in the pathogenesis of various types of ARDS and has attracted increasing research attention. ARDS caused by different etiologies exhibits distinct pathophysiological characteristics, and the role of ferroptosis varies significantly among them. The following will focus on infection-related ARDS (including viral and bacterial), sepsis-associated ARDS, ischemia–reperfusion injury-related ARDS, and radiation-induced lung injury-related ARDS, respectively, elucidating the specific roles and potential mechanisms of ferroptosis in each type. Characteristics of ferroptosis in infectious ARDS Viral ARDS ARDS caused by SARS-CoV-2 infection is a typical example of viral ARDS, characterized by prominent inflammatory cell infiltration, a “cytokine storm,” and extensive alveolar epithelial injury. After SARS-CoV-2 infection, alveolar macrophages and pulmonary epithelial cells are activated, releasing large amounts of pro-inflammatory cytokines, such as Interleukin-6, TNF, and IL-1β; these cytokines increase pulmonary endothelial permeability, impair barrier function, facilitate viral dissemination, and promote infiltration of neutrophils and inflammatory monocytes, thereby triggering ARDS [19]. Elevated levels of multiple ferroptosis markers have been detected in lung tissues of severe COVID-19 patients, including increased expression of transferrin receptor 1 (TfR1) and significant accumulation of the lipid peroxidation end product malondialdehyde (MDA). Meanwhile, COVID-19 patients exhibit severe disruption of pulmonary iron homeostasis, manifesting as hyperferritinemia and a tendency toward iron overload [20]. Qiu et al. [20] demonstrated through immunohistochemistry and lipidomics analyses of lung tissues from deceased COVID-19 patients that ferroptosis is significantly activated in fatal COVID-19-associated lung injury. Zhou et al. [21] found that hepcidin levels in severe COVID-19 patients were markedly higher than those in mild cases and healthy controls; this elevation is likely related to inflammatory responses rather than simple iron overload. As a key regulator of iron metabolism, elevated hepcidin may cause iron retention in lung tissues, thereby exacerbating oxidative stress and inflammatory responses [22]. Liu et al. [23] observed that in COVID-19 patients, lipid peroxidation markers such as MDA were significantly elevated, while the expression of glutathione peroxidase 4 (GPX4) was reduced, suggesting that viral infection may exacerbate disease severity by promoting oxidative stress. Bacterial ARDS Bacterial ARDS is a severe pulmonary disease caused by bacterial infection, typically associated with high mortality and complex pathophysiological processes [24]. Represented by the lipopolysaccharide (LPS)-induced mouse model, bacterial ARDS exhibits ferroptosis characteristics marked by significant iron homeostasis imbalance and suppression of the GPX4 pathway. Studies indicate that after LPS exposure, free Fe2⁺ levels in mouse lung tissue increase, while GPX4 expression significantly decreases, resulting in pronounced lipid peroxidation. Treatment with the ferroptosis-specific inhibitor Ferrostatin-1(Fer-1) markedly alleviates lung injury, suggesting that ferroptosis participates in and promotes the progression of bacterial ARDS [25]. Bacterial infection can also directly induce ferritinophagy, releasing stored iron ions and thereby further exacerbating intracellular ferroptosis. Ferritinophagy is a selective autophagy process mediated by nuclear receptor coactivator 4 (NCOA4), during which ferritin is degraded, releasing large amounts of Fe2⁺ that elevate intracellular ROS levels and trigger ferroptosis [26]. Characteristics of ferroptosis in sepsis-associated ARDS Sepsis-associated ARDS is the most common clinical subtype of ARDS, characterized pathologically by severe systemic inflammatory responses. This inflammatory response typically causes disruption of the alveolar–capillary barrier, leading to lung injury manifested as hypoxemia, inflammation, and non-cardiogenic pulmonary edema [27]. Studies have demonstrated that ferroptosis plays a critical role in the onset and progression of sepsis [28]. Ferroptosis influences disease progression through multiple mechanisms. For example, oxidative products and damage-associated molecular patterns (DAMPs) generated during ferroptosis can activate various pattern recognition receptors (PRRs), triggering inflammatory cascades and resulting in excessive release of inflammatory cytokines [29]. This inflammatory response not only exacerbates sepsis-associated ARDS but may also lead to multiple organ dysfunction syndrome (MODS), thereby increasing patient mortality [30]. In sepsis-associated ARDS, ferroptosis can also modulate the inflammatory response and lipid peroxidation to mitigate the impact of sepsis. Ferroptosis inhibitors and drugs, especially those targeting critical processes, such as the Xc- system, nuclear factor erythroid 2-related factor 2 (Nrf2)/GPX4 axis, and NCOA4- ferritin heavy chain 1(FTH1)-mediated ferritinophagy, have shown promising potential in alleviating sepsis [31]. Furthermore, studies have found that ferroptosis is closely associated with immune cell infiltration in sepsis-associated ARDS. Through machine learning and bioinformatics analyses, several ferroptosis-related key genes, such as interleukin 1 beta (IL1B), mitogen-activated protein kinase 3(MAPK3), and thioredoxin (TXN), have been identified as potential diagnostic biomarkers for sepsis-associated ARDS [32]. These findings provide new insights for the early diagnosis and treatment of sepsis-associated ARDS. In summary, ferroptosis plays a complex and multifaceted role in the pathogenesis of sepsis-associated ARDS. A deeper understanding of its molecular mechanisms and regulatory networks may pave the way for the development of novel therapeutic strategies aimed at improving patient survival and quality of life. Characteristics of ferroptosis in ischemia–reperfusion injury-related ARDS Ischemia–reperfusion injury refers to the pathological process in which tissue damage is exacerbated when blood flow is restored after a period of ischemia. Due to its highly dense capillary network, the lung is particularly susceptible to ischemia–reperfusion injury, and once ARDS occurs, the mortality rate is high with a lack of effective specific treatments. ARDS caused by ischemia–reperfusion injury is commonly observed after major surgeries and severe trauma, characterized pathologically by a massive generation of oxidative stress during reperfusion. The generation of oxidative stress during reperfusion is a hallmark of ischemia–reperfusion injury, and this stress state leads to the production of a large amount of reactive oxygen species, thereby exacerbating tissue damage [33, 34]. Recent studies have demonstrated that ferroptosis plays a critical role in ARDS induced by ischemia–reperfusion injury. In a mouse model of intestinal ischemia–reperfusion-induced ALI, ferroptosis is considered one of the key mechanisms involved in the pathological process. Xu et al. [35] confirmed that inhibiting ferroptosis and acyl-CoA synthetase long-chain family member 4 (ACSL4) can effectively alleviate ischemia–reperfusion injury. This mechanism is mainly achieved by reducing lipid peroxidation and increasing levels of GSH and GPX4. In pulmonary ischemia–reperfusion injury, inhibition of ACSL4 can alleviate ferroptosis by reducing lipid peroxidation and iron content, thereby improving lung function. Li et al. [36] showed that the tumor suppressor p53 can regulate ferroptosis, while the p53-interacting protein iASPP, acting as a p53 inhibitor, can suppress ferroptosis by activating the Nrf2 signaling pathway, thereby alleviating intestinal ischemia–reperfusion-induced ALI. Therefore, regulating ferroptosis during ischemia–reperfusion has significant implications for the prevention and treatment of this type of ARDS. Characteristics of ferroptosis in ARDS associated with radiation-induced lung injury Radiation-induced lung injury (RILI) is one of the common and severe complications of thoracic radiotherapy. Ferroptosis, as a novel form of cell death, plays an important role in RILI. During the process of radiation-induced lung injury, ferroptosis may be triggered by radiation-induced ROS [37]. In addition, ferroptosis is closely associated with the progression of radiation-induced pulmonary fibrosis and may accelerate the fibrotic process by promoting extracellular matrix remodeling [38]. In therapeutic studies of radiation-induced lung injury, inhibition of ferroptosis is considered a potential treatment strategy. For example, NVP–AUY922 significantly ameliorated radiation-induced lung tissue damage and inflammatory cell infiltration by inhibiting the ferroptosis pathway [39]. Furthermore, naringenin, a natural flavonoid compound, has also been found to alleviate radiation-induced lung injury by inhibiting ferroptosis [40]. In summary, ferroptosis plays an important pathophysiological role in radiation-induced lung injury, and interventions targeting ferroptosis may offer new insights and approaches for its treatment. The characteristics of ferroptosis in different types of ARDS are shown in Table 1. Table 1Characteristics of ferroptosis in different types of ARDSType of ARDSMain Triggers and FeaturesFerroptosis CharacteristicsKey Molecular Mechanisms and MarkersViral ARDSViral infection, cytokine storm, alveolar damageSignificant activation of ferroptosis, iron homeostasis imbalance↑TfR1, ↑MDA, ↓GPX4; increased hepcidin, iron overload; hyperferritinemia [20, 23]Bacterial ARDSLPS-induced, strong inflammatory responseActivation of ferroptosis, increased iron release↑Free Fe2⁺, ↓GPX4, ↑NCOA4-mediated ferritinophagy [25, 26]Sepsis-associated ARDSSystemic inflammation, disruption of pulmonary capillary barrierFerroptosis exacerbates lung injury, DAMPs promote inflammation↑ROS, impaired Xc⁻ system, inhibited GPX4/Nrf2 pathway, ↑IL1B, MAPK3, TXN [28, 32]Ischemia–reperfusion-related ARDSROS surge upon reperfusion, oxidative stressACSL4 activation → lipid peroxidation ↑ → ferroptosis↓GSH, ↓GPX4, ↑ACSL4, p53 regulation of Nrf2/iASPP axis [35, 36]Radiation-induced ARDSROS production post-radiation, inflammation and fibrosis developmentFerroptosis promotes lung tissue damage and fibrosis↑ROS, activation of ferroptosis-related signaling [37, 38] Characteristics of ferroptosis in different types of ARDS The interaction mechanism between ferroptosis and ARDS Recent studies highlight a bidirectional relationship between ferroptosis and ARDS. Pathological conditions inherent to ARDS, such as oxidative stress and systemic inflammation, create an environment conducive to ferroptosis [41]. This process manifests through hallmark features, including lipid peroxidation accumulation, iron overload, and dysregulation of ferroptosis-related proteins. Conversely, ferroptotic cell death exacerbates ARDS progression by releasing pro-inflammatory mediators, which amplify pulmonary inflammation and tissue damage, perpetuating a detrimental feedback loop [42]. At the molecular level, key signaling pathways mediate this interaction. For instance, the Nrf2 pathway, which normally suppresses ferroptosis via antioxidant mechanisms, is impaired in ARDS, further sensitizing cells to iron-dependent death [43]. In addition, ferroptosis-induced endothelial dysfunction, driven by histone H3 lysine 14 lactylation-mediated solute carrier family 40 member A1/transferrin activation, contributes to vascular injury, underscoring its role in ARDS pathophysiology [44]. Ferroptosis-targeted therapeutic agents Pharmacological interventions targeting ferroptosis offer novel strategies for the treatment of ARDS. Ferroptosis inhibitors, such as ferrostatin-1 and liproxstatin-1, are important drugs that block ferroptosis by inhibiting lipid peroxidation. In animal studies, administration of ferrostatin-1 significantly alleviated lung injury, reduced inflammation, and improved pulmonary function in LPS-induced ARDS mouse models, suggesting its potential therapeutic value in ARDS [45]. Ferroptosis-targeted intervention strategies mainly include iron chelators, lipid peroxidation inhibitors, enhancers of antioxidant systems, and modulators of lipid-metabolizing enzymes. Iron chelators inhibit ferroptosis by reducing intracellular iron levels. Studies have shown that iron chelators like deferoxamine effectively prevent ferroptosis and exhibit therapeutic potential in various disease models [46, 47]. Lipid peroxidation inhibitors such as ferrostatin-1 and liproxstatin-1 block ferroptosis by suppressing lipid peroxidation reactions. Antioxidant system enhancers, such as GPX4, play a critical role in the regulation of ferroptosis. GPX4 inhibits ferroptosis by reducing oxidized fatty acids in the cell membrane. Modulating lipid-metabolizing enzyme activity is also an important component of ferroptosis-targeted strategies. Regulation of lipid metabolic pathways can effectively control the occurrence of ferroptosis. Commonly used ferroptosis inhibitors include ferrostatin-1, liproxstatin-1, and iron chelators, such as deferoxamine (DFO), all of which have demonstrated significant protective effects in various ARDS/ALI animal models [11]. For example, Liu et al. [48] observed that in an LPS-induced murine acute lung injury model, Fer-1 treatment significantly reduced histological lung damage, decreased inflammatory cytokines in bronchoalveolar lavage fluid (BALF), and corrected LPS-induced changes in iron metabolism and oxidative stress markers. Other studies have shown that ferrostatin-1 and liproxstatin-1 treatment improved lung pathology, reduced pulmonary edema, and decreased lipid peroxidation levels in pulmonary ischemia–reperfusion injury models [10, 36]. In ventilation-induced lung injury models, ferrostatin-1 has also been reported to improve lung function and reduce inflammation by inhibiting the ferroptosis pathway [49]. Moreover, Wu et al. [50] found that the antioxidant RTA408 alleviated LPS-induced acute lung injury by inhibiting the Bach1-mediated ferroptosis pathway. In addition, some natural compounds have been found to modulate ferroptosis. For instance, quercetin and kaempferol can activate the Nrf2 signaling pathway, upregulate antioxidant proteins like GPX4, inhibit ferroptosis, and exert protective effects against ARDS [51]. The traditional Chinese medicine component Astragaloside IV inhibits PM2.5-induced lung injury by activating the Nrf2/solute carrier family 7 member 11(SLC7A11)/GPX4 axis [52]. In summary, various ferroptosis inhibitors have demonstrated lung-protective effects in different ARDS animal models, providing a rationale for developing future ferroptosis-targeted therapies. Ferroptosis and clinical research Clinically, research on ferroptosis in ARDS mainly focuses on biomarker exploration and validation using patient samples. A recent study analyzing bronchoalveolar lavage fluid from ARDS patients found that the expression of ferroptosis-related genes and proteins was significantly associated with disease severity. They identified three key ferroptosis-related genes, such as CP (ceruloplasmin), SLC7A11, and Solute Carrier Family 39 Member 14, and validated them in BALF samples from 59 ARDS patients. CP expression was elevated in severe ARDS cases, SLC7A11 expression was significantly higher in moderate ARDS compared to mild cases, and peripheral neutrophil count positively correlated with SLC7A11 expression [10]. Moreover, several studies suggest that ferroptosis-related markers may serve as potential prognostic biomarkers in ARDS patients. For instance, the expression levels of ferroptosis-related proteins such as GPX4 and Nrf2 in lung tissues or BALF from ARDS patients are associated with disease severity and prognosis. Low expression of GPX4 and Nrf2 is often associated with poorer outcomes, suggesting that activation of ferroptosis may indicate worsening of ARDS [43]. Although standardized clinical indicators for ferroptosis are currently lacking, assessing GSH/GPX4 system function, lipid peroxidation products, and iron metabolism-related proteins in ARDS patients may provide valuable diagnostic and prognostic insights. Further clinical cohort studies are needed to validate the role of ferroptosis biomarkers in ARDS classification and treatment. In addition, although clinical trials on ferroptosis inhibitors in ARDS treatment are relatively limited, some studies have shown promising efficacy and safety. Based on animal studies, certain ferroptosis inhibitors have entered early clinical trial stages. For example, in a preliminary clinical trial involving sepsis-induced ARDS patients, administration of a ferroptosis inhibitor improved inflammatory markers and partially restored lung function; however, due to the small sample size, further studies with larger cohorts are needed to confirm efficacy and safety [53]. Some drugs already proven to inhibit ferroptosis in other diseases may also offer therapeutic insights for ARDS. For instance, dipyridamole has been shown in vitro to inhibit ferroptosis in pulmonary epithelial and endothelial cells, reduce lung injury in animal models of ARDS, and demonstrated therapeutic potential in a preliminary clinical trial, offering a new option for ARDS treatment [54]. However, clinical trials must continue to address issues such as drug dosage and side effects to ensure both efficacy and safety. Controversies of ferroptosis in ARDS research Although the association between ferroptosis and ARDS has been widely studied, the specific mechanisms of ferroptosis in ARDS remain controversial. On one hand, the initiating and driving factors of ferroptosis in the development of ARDS have not been fully elucidated. Although inflammation and oxidative stress are believed to be involved in the induction of ferroptosis, there is still debate over which specific signaling pathways and molecular events play key roles. For example, some studies suggest that suppression of the Nrf2 signaling pathway is a critical trigger for ferroptosis. In contrast, other studies have identified activation of the p53 signaling pathway as the dominant driver of ferroptosis induction. These discrepancies may be attributed to differences in experimental models, sample sources, and other factors [43, 55]. On the other hand, the relationship between ferroptosis and other forms of cell death, such as apoptosis and necrosis, is also controversial. During the pathogenesis of ARDS, multiple forms of cell death may coexist and interact with each other. It remains unclear whether ferroptosis acts independently or synergistically with other types of cell death to contribute to lung injury. Some studies suggest that ferroptosis may indirectly promote apoptosis by activating certain apoptosis-related signaling pathways. For instance, in Parkinson’s disease models, ferroptosis precedes apoptosis in iron overload-induced cell death. Moreover, ferroptosis could be inhibited by the use of apoptosis inhibitors, suggesting that ferroptosis may trigger apoptosis under certain conditions [56]. In contrast, other studies propose that ferroptosis and apoptosis are independent processes. For example, in alcohol-induced liver injury models, ferroptosis and apoptosis exhibit distinct response patterns. Ferroptosis inhibitors significantly alleviated liver injury, while apoptosis inhibitors showed no comparable effect [57]. In addition, in certain cancer therapies, ferroptosis and apoptosis are considered to occur independently via distinct signaling pathways [58]. These controversies require further in-depth investigation for clarification. The efficacy and safety of ferroptosis-targeted therapy in ARDS are also subjects of debate. Regarding efficacy, although ferroptosis inhibitors and other targeted approaches have shown therapeutic effects in animal studies, such as reducing lung injury and improving inflammatory responses, their clinical efficacy may be influenced by various factors due to the complexity of the human body and disease heterogeneity. For instance, patient responses to ferroptosis inhibitors may vary. Some patients may exhibit different sensitivities to the drugs due to genetic background or comorbidities, leading to suboptimal treatment outcomes [53]. In terms of safety, ferroptosis-targeted therapies may pose potential side effects. Ferroptosis is an essential physiological regulatory mechanism in cells, and excessive inhibition may disrupt normal cellular functions. For example, prolonged use of ferroptosis inhibitors could disturb iron homeostasis and adversely affect other organ systems. Therefore, safety must be thoroughly evaluated when implementing ferroptosis-targeted therapies, and the optimal therapeutic dose and regimen should be identified to ensure both efficacy and safety. Future perspectives of ferroptosis research in ARDS Emerging technologies have brought new opportunities for studying ferroptosis in ARDS. Gene editing technologies such as the CRISPR–Cas9 system can precisely modify ferroptosis-related genes, facilitating in-depth exploration of the molecular mechanisms of ferroptosis in ARDS. By constructing animal models with knockout or overexpression of ferroptosis-related genes, researchers can more accurately understand the role of these genes in the onset and progression of ARDS, providing a basis for developing new therapeutic targets [59]. In addition, nanotechnology holds potential application value in ferroptosis-based therapies. Nanocarriers can deliver ferroptosis-targeted drugs precisely to lung lesions, enhancing therapeutic efficacy while minimizing side effects. For example, nanoparticles responsive to the pulmonary microenvironment can be designed to release ferroptosis inhibitors in the inflamed lung regions of patients with ARDS, achieving targeted therapy [60]. Meanwhile, the integrated application of multi-omics technologies (such as genomics, transcriptomics, proteomics, and metabolomics) can comprehensively elucidate the molecular regulatory networks of ferroptosis in ARDS, offering broader perspectives for identifying novel biomarkers and therapeutic targets [45]. Ferroptosis research in ARDS is showing a trend toward interdisciplinary collaboration. Biological studies have unveiled the molecular mechanisms and signaling pathways of ferroptosis, laying a theoretical foundation for treatment, while medical research validates the efficacy and safety of ferroptosis-based therapies through clinical studies, promoting clinical translation. For instance, once basic medical research identifies new ferroptosis-related targets, clinical medicine can conduct trials to evaluate the efficacy and safety of drugs targeting these molecules in ARDS patients [53]. However, the current clinical evidence base for ferroptosis-targeted therapies in ARDS remains critically limited. Existing studies, predominantly focus on preclinical mechanistic insights or candidate compounds derived from animal models, which may not fully recapitulate the pathophysiological complexity of human ARDS. To date, no phase II/III clinical trials have validated the therapeutic potential of ferroptosis inhibitors in ARDS populations, and key challenges in trial design persist. These include: (1) defining clinically relevant endpoints (e.g., mortality and ventilator-free days) that align with the heterogeneity of ARDS subphenotypes; (2) addressing interpatient variability through biomarker-driven stratification strategies to identify subgroups most likely to benefit from ferroptosis modulation; (3) ensuring adequate statistical power in trials, given the low sample sizes reported in preclinical and early phase studies; and (4) evaluating safety profiles of ferroptosis modulators, particularly their interactions with standard ARDS therapies (e.g., mechanical ventilation and vasopressors) and potential off-target effects on physiological redox homeostasis. Future translational efforts should prioritize multicentre phase II trials to establish dose–response relationships, refine patient selection criteria, and generate robust evidence for progression to phase III evaluation. Such studies will be critical in bridging the current gap between mechanistic discovery and clinical implementation of ferroptosis-targeted therapies in ARDS. Furthermore, engineering and materials science can support the development of novel ferroptosis-targeted drugs and delivery systems. For example, materials scientists can design smart nanomaterials for targeted delivery of ferroptosis drugs to enhance therapeutic outcomes; engineers can improve medical devices, such as optimizing ventilator designs, in combination with ferroptosis therapy to better treat ARDS patients. Interdisciplinary collaboration will accelerate advancements in ferroptosis research in ARDS, offering better therapeutic prospects for patients. There are several potential breakthroughs in the application of ferroptosis in ARDS treatment. First, developing more specific and effective ferroptosis modulators is essential. Although current ferroptosis inhibitors show some efficacy, issues such as specificity and safety remain. In the future, highly specific modulators targeting key ferroptosis molecules and pathways are needed, for example, designing small molecules that precisely regulate GPX4 activity to inhibit ferroptosis effectively while minimizing impact on normal cellular physiology [61]. Second, optimizing combination therapy strategies is another potential breakthrough. Beyond combining with anti-inflammatory drugs, exploring the integration of ferroptosis therapies with immunotherapy and gene therapy may yield improved therapeutic outcomes. For example, modulating ferroptosis may enhance immune cell clearance of pulmonary inflammation in ARDS, or gene therapy may correct aberrant expression of ferroptosis-related genes both holding promise for breakthrough treatments in ARDS [59]. Moreover, a deeper understanding of individual differences in ferroptosis could enable personalized treatments, tailoring ferroptosis-targeted therapies based on patients’ genetic backgrounds and disease characteristics an important direction for future development. Acknowledgements None. Author contributions Y.Z. conducted the literature review, drafted the manuscript, and prepared the figures. J.L. and Z.T. contributed to data collection and critical revision of the manuscript. H.G. conceived and supervised the study, and provided final approval of the version to be published. All authors reviewed and approved the final manuscript. Funding This work was supported by the Sichuan Medical and Health Care Promotion Institute Scientific Research Project (Grant No. KY2024SJ0081). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication There are no objections to the publication of this manuscript. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.